| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/28/2002 | WO2002024657A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | WO2002024653A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | WO2002024647A1 Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| 03/28/2002 | WO2002024635A2 Aminoalcohol derivatives |
| 03/28/2002 | WO2002024633A1 Phenylpropionic acid derivatives |
| 03/28/2002 | WO2002024632A2 Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| 03/28/2002 | WO2002024307A2 Reducing the content of particular cell types in a biological sample |
| 03/28/2002 | WO2002024222A2 Ligands for g protein coupled receptors and methods of using them |
| 03/28/2002 | WO2002024214A2 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 03/28/2002 | WO2002024213A2 Improved protocol for paracentesis |
| 03/28/2002 | WO2002024204A2 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 03/28/2002 | WO2002024200A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 03/28/2002 | WO2002024194A2 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 03/28/2002 | WO2002024193A1 Stabilised fibrate microparticles |
| 03/28/2002 | WO2002024180A2 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 03/28/2002 | WO2002024169A1 Spray drying process and compositions of fenofibrate |
| 03/28/2002 | WO2002024165A2 Preparation of vitamin emulsions and concentrates thereof |
| 03/28/2002 | WO2002024162A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | WO2002024002A2 Food supplement |
| 03/28/2002 | WO2002004624A9 Novel g protein-coupled receptor protein and dna thereof |
| 03/28/2002 | WO2001097751A3 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 03/28/2002 | WO2001094952A3 Methods and compositions for modulating oxidized ldl transport |
| 03/28/2002 | WO2001090106A3 Tryasolyl tropane derivatives as ccr5 modulators |
| 03/28/2002 | WO2001087861A3 Methods of treatment using benzoxazinones as peroxisome proliferator activated receptor gamma modulators |
| 03/28/2002 | WO2001087860A3 Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment |
| 03/28/2002 | WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents |
| 03/28/2002 | WO2001083434A3 P-(sulfonyl)-aryl and heteroaryls amines |
| 03/28/2002 | WO2001072279A3 Medical emulsion for lubrication and delivery of drugs |
| 03/28/2002 | WO2001070977A3 Fibroblast growth factor receptor-like molecules and uses thereof |
| 03/28/2002 | WO2001061359A3 Identification of modulators of gpr41 or gpr42 activity |
| 03/28/2002 | WO2001055356A3 Human protein kinases and protein kinase-like enzymes |
| 03/28/2002 | WO2001052825A3 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 03/28/2002 | WO2001045484A3 An improved process for preparing simvastatin |
| 03/28/2002 | WO2001032216A3 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 03/28/2002 | WO2001023377A9 Polymorphic salt |
| 03/28/2002 | WO2001015674A3 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| 03/28/2002 | WO2001007405A3 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 03/28/2002 | WO2000066102A3 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| 03/28/2002 | WO2000060051A3 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 03/28/2002 | US20020038028 For therapy of neurological and psychological disorders are claimed. |
| 03/28/2002 | US20020038025 For therapy and prophylaxis of hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, diabetes |
| 03/28/2002 | US20020038002 To suppress immune system for therapy of symptoms associated with immune disorders such as allergies, transplanted tissue rejection and autoimmune diabetes, rheumatoid arthritis and multiple sclerosis |
| 03/28/2002 | US20020037928 For treatment of diabetes mellitus; for example sulfonamide derivatives of given formula and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists |
| 03/28/2002 | US20020037927 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/28/2002 | US20020037915 4-(4-(1- phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5-methylthiothiophene-2 -carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases |
| 03/28/2002 | US20020037911 Arylthiazolidinedione derivatives |
| 03/28/2002 | US20020037910 Novel anilide compounds and pharmaceutical compositions comprising them |
| 03/28/2002 | US20020037909 Enamine derivatives |
| 03/28/2002 | US20020037895 Wherein the lactone ring is modified; preventing or treating disorders or diseases mediated by LFA-1 (Leukocyte Function-associated Antigen-1) ICAM-1 (intercellular adhesion molecules) interactions; autoimmune disorders, inflammation |
| 03/28/2002 | US20020037892 Bis-arylsulfones |
| 03/28/2002 | US20020037882 Mixture containing glyceride |
| 03/28/2002 | US20020037878 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/28/2002 | US20020037861 Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X |
| 03/28/2002 | US20020037850 Genetic engineering; binding to antibodies |
| 03/28/2002 | US20020037836 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| 03/28/2002 | US20020037830 Adjust glycogen concentration |
| 03/28/2002 | US20020037577 Microorganisms for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same |
| 03/28/2002 | US20020037561 Method for producing arachidonic acid |
| 03/28/2002 | US20020037549 ABC transport polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections |
| 03/28/2002 | US20020037332 Licorice extract for use as a medicament |
| 03/28/2002 | US20020035997 Method and bottle for infant feeding |
| 03/28/2002 | DE10042625A1 Deodorizing apparatus for sewage line, has deodorizing tower with deodorizing layer, catalytic reaction tower with catalyst for reacting catalyst with deodorized gas to form odorless gas |
| 03/28/2002 | DE10042447A1 Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports Protein from the intestines of vertebrates, which absorbs cholesterol, as well as use of this protein for the identification of inhibitors of intestinal cholesterol transport |
| 03/28/2002 | CA2423156A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 03/28/2002 | CA2423106A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | CA2422911A1 New inhibitors of iapp fibril formation and uses thereof |
| 03/28/2002 | CA2422820A1 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 03/28/2002 | CA2422686A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | CA2422671A1 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2421823A1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | CA2420862A1 Protein phosphatases |
| 03/28/2002 | CA2416136A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 03/28/2002 | CA2357853A1 Use of growth hormone secretagogues in conjunction with physical exercise |
| 03/27/2002 | EP1191019A1 Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof |
| 03/27/2002 | EP1190717A2 Licorice extract for use as a medicament |
| 03/27/2002 | EP1190710A1 Preventive or therapeutic drugs for diabetes |
| 03/27/2002 | EP1190099A1 Antisense modulation of pi3k p85 expression |
| 03/27/2002 | EP1190086A2 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 03/27/2002 | EP1190072A2 22012, a novel human carboxypeptidase |
| 03/27/2002 | EP1190071A2 17867, a novel human aminopeptidase |
| 03/27/2002 | EP1190065A2 Atp binding cassette transporter protein abc1 polypeptides |
| 03/27/2002 | EP1190063A1 Nucleic and proteinic acids corresponding to human gene abc1 |
| 03/27/2002 | EP1190059A1 Sgip peptides |
| 03/27/2002 | EP1190052A1 16405 receptor, a g-protein coupled receptor |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1190038A2 Bacterial protection against stress |
| 03/27/2002 | EP1189942A1 Somatostatin agonists |
| 03/27/2002 | EP1189941A1 Neuromedin b and somatostatin receptor agonists |
| 03/27/2002 | EP1189924A1 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 03/27/2002 | EP1189923A1 Aromatic and heterocyclic derivatives of phytosterols and/or phytostanols for use in treating or preventing cardiovascular disease |
| 03/27/2002 | EP1189922A1 Steroid derivatives |
| 03/27/2002 | EP1189917A1 48 human secreted proteins |
| 03/27/2002 | EP1189905A1 Substituted heterocycle fused gamma-carbolines |
| 03/27/2002 | EP1189904A1 Substituted heterocycle fused gamma-carbolines |
| 03/27/2002 | EP1189903A1 Novel benzo f]naphthyridine, preparation and compositions containing them |
| 03/27/2002 | EP1189895A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 03/27/2002 | EP1189890A1 Dihydrobenzodiazepins and their use for treating dyslipidemia |